Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GATA: Atezolizumab, Venetoclax, and Obinutuzumab in R/R Lymphoma
NCT03276468Phase 2Completed
- Sponsor
- LYSARC
- Start
- Feb 2018
- Primary completion
- Sep 2019
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, venetoclax, obinutuzumab in follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), mucosa associated lymphoid tissue lymphoma, sponsored by LYSARC. Started Feb 2018; status: completed.
02
Drugs
atezolizumabvenetoclaxobinutuzumab
03
Conditions
follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)marginal zone lymphoma (MZL)mucosa associated lymphoid tissue lymphoma
Beyond the preview
Go deeper on NCT03276468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03276468.